New Anti-CD-19 And BCMA Options
from OncoPharm Hosted by John Bossaer
Lots of new options for B-cell malignancies of all ages! We discuss brexucabtagene autoleucel (CAR-T for mantle cell lymphoma, tafasitamab (anti CD-19 monoclonal antibody), and belantamab mafadotin (anti-BCMA antibody drug conjugate). Finally, for good measure we review the newly approved regimen of atezolizumab with vemurafenib/cobimetinib for BRAF-mutated metastatic melanoma.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 21 minutes long.
When was this OncoPharm episode published?
This episode was published on August 6, 2020.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.